Filtering perfusion type wearable artificial kidney device

Through the filtering perfusion artificial kidney device, the three-layer ultrafiltrate perfusion device and the blood filter are used to solve the problems of high cost of adsorption consumables and low urea removal efficiency, and blood purification without liquid consumables is achieved, and the cost is reduced. Improves portability and removal efficiency.

CN222033206UActive Publication Date: 2024-11-22SICHUAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202422580249.6
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-11-22
Estimated Expiration
2034-10-25

AI Technical Summary

Technical Problem

The existing wearable artificial kidney devices have limited the popularity and application of the device due to the high cost and limited efficiency of adsorption consumables, especially the low urea removal efficiency. The traditional equipment has large weight, poor portability and limited applicability.

Method used

Using a filter perfusion artificial kidney device, combined with a hemofiltration filter and a three-layer ultrafiltrate perfusion device, the metabolic waste and toxins in the blood are removed through the adsorption layer of polyethersulfone resin, polystyrene resin and activated carbon resin, avoiding dialysis. The use of liquid and replacement liquid improves the portability and removal efficiency of the device.

Benefits of technology

It realizes blood purification without dialysate and replacement fluid, reduces usage costs, improves urea removal efficiency, is suitable for ordinary low-income families, and avoids the safety risks brought about by urease decomposition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN222033206U_ABST
    Figure CN222033206U_ABST
Patent Text Reader

Abstract

The utility model discloses a filtration perfusion type wearable artificial kidney device, which belongs to the technical field of blood purification, the device comprises a blood circulation part and an ultrafiltrate purification part, the blood circulation part comprises an artery clamp (1), a blood pump (3), a heparin inlet (4), an artery pot (5), a blood filter (7), a vein pot (13), a bubble detector (14) and a vein clamp (16) which are arranged in sequence; the ultrafiltrate purification part comprises an ultrafiltrate pump (9) and a three-layer ultrafiltrate perfusion device (12) which are arranged in sequence; according to the device, a complicated water treatment system and a dialysate circulating device are not needed, and metabolic wastes and toxins in blood are indirectly removed through an ultrafiltrate perfusion device of the ultrafiltrate purification part, so that the treatment process is simplified, and the portability of the artificial kidney device is improved. In addition, when metabolic waste and toxin are removed, the perfusion device is prevented from being in direct contact with blood, and the safety of artificial kidney treatment is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model relates to the technical field of blood purification, in particular to a filtration perfusion type wearable artificial kidney device. Background Art

[0002] Uremia is the terminal stage of renal failure. The number of uremia patients in China has increased year by year. From 2000 to 2020, the total number of uremia patients has increased from 100,000 to more than 2 million. Artificial kidney is an important way to treat renal failure and uremia. It can replace the function of human kidney to a certain extent. It can remove metabolic waste and toxins from the blood by drawing the patient's blood out of the body through hemodialysis machines, hemoperfusion devices, etc., to achieve the purpose of purifying blood and treating diseases.

[0003] Traditional artificial kidney treatment needs to be completed in large hospitals, hemodialysis centers and other medical institutions, which is inconvenient and has a great impact on patients' work and life. Wearable artificial kidneys mainly use portable blood purification devices to complete blood purification treatment in the community or at home. Its advantage is that the lightweight and miniaturized treatment device has less impact on patients' work and life. At present, the research and development of wearable artificial kidneys is mainly concentrated in three directions: dialysis wearable artificial kidneys, perfusion wearable artificial kidneys and combined wearable artificial kidneys.

[0004] The dialysis-type wearable artificial kidney needs to solve the problem of the source of dialysate: the dialysate disposable artificial kidney device can be connected to a small water treatment system or bagged dialysate, and home dialysis can be achieved by modifying the family's water and electrical circuits. It is currently used at a high rate in European and American countries. However, the equipment is expensive. Due to the presence of the water treatment system, the weight of the equipment is at least 30kg, and more than 100L of dialysate is used for a single treatment. In addition, the requirements for water sources and water quality are high, which is not suitable for ordinary low-income families. The dialysate regeneration artificial kidney device includes a dialysate regeneration system, which uses adsorbents to remove harmful components in the dialysis waste fluid. The regenerated dialysate is reused for dialysis treatment, which greatly reduces the use of dialysate. Only 2-6L of dialysate is used for a single treatment. The device does not require a complex water treatment system, the equipment is small and convenient, and can be made less than 10 kg, which is suitable for home purchase and use. However, the adsorption consumables used in this device are expensive, and the efficiency of the adsorbent in removing harmful components in the dialysis waste fluid will gradually decrease with the increase of dialysis time. The adsorption consumables need to be replaced in time during the treatment process, so its practical application is also limited.

[0005] The perfusion-type wearable artificial kidney uses a blood perfusion device / plasma perfusion device to remove metabolic waste and toxins from the blood. The perfusion device is composed of multiple adsorption modules, which are used to adsorb urea, uric acid, creatinine and β2-microglobulin in the blood, and then the purified blood / plasma is returned to the patient. Its core problem is similar to that of the dialysate regeneration artificial kidney. The adsorption consumables are costly and have limited efficiency, and this model has high requirements on the blood compatibility and safety of the adsorbent itself. The combined wearable artificial kidney is a treatment model that combines hemodialysis and hemoperfusion. To a certain extent, it reduces the use of consumables and ensures the portability of the device, but it does not fundamentally solve the problem of limited efficiency of dialysate regeneration and adsorption consumables.

[0006] The problem of urea removal is another important reason that limits the development of wearable artificial kidneys. It is difficult to remove urea from both the dialysate regeneration system and the adsorbent in the perfusion device. Removing urea by direct adsorption is the best solution in theory, but so far, there has been no successful application of efficient urea adsorption materials; urea can be removed by the "urease decomposition-adsorption" strategy, but the blood ammonia produced by urea decomposition is more harmful to the human body, and additional adsorbents are needed to remove blood ammonia. In addition, the high price of urease and the unstable decomposition activity also limit the application of this method.

[0007] Most of the various wearable artificial kidney devices currently developed internationally and domestically have not made it to clinical trials due to the above technical bottlenecks, and some wearable artificial kidney devices that have been put into practical use are also difficult to promote due to limited use conditions. Therefore, this field is in urgent need of a new artificial kidney device that, while ensuring that the device is light and easy to carry, reduces the amount of fluid (dialysis fluid and replacement fluid) and adsorption consumables, reduces treatment costs, and at the same time improves treatment efficiency, especially the removal efficiency of urea. Utility Model Content

[0008] In order to solve the above problems, the purpose of the utility model is to provide a filtration perfusion wearable artificial kidney device, which applies a blood filter and a three-layer ultrafiltrate perfusion device to the artificial kidney device, continuously removes toxins, metabolic waste and moisture in the blood, does not use dialysate and replacement fluid, improves the portability of the device and reduces the cost of use.

[0009] The technical solution adopted by the utility model is:

[0010] A filtration perfusion wearable artificial kidney device comprises a blood circulation part and an ultrafiltrate purification part; wherein:

[0011] The blood circulation part includes an arterial clamp, a blood pump, a heparin inlet, an arterial pot, a blood filter, a venous pot, a bubble detector and a venous clamp which are sequentially arranged along the blood flow direction;

[0012] The ultrafiltrate purification part includes an ultrafiltrate pump and a three-layer ultrafiltrate perfusion device arranged in sequence along the flow direction of the ultrafiltrate, which can continuously remove metabolic waste and toxins in the ultrafiltrate; an ultrafiltrate clamp and an ultrafiltrate collector are arranged between the ultrafiltrate pump and the three-layer ultrafiltrate perfusion device, which can discharge part of the ultrafiltrate to achieve the effect of dehydration; the blood pump controls the blood flow rate of the blood circulation part; the ultrafiltrate pump controls the ultrafiltrate flow rate of the ultrafiltrate purification part;

[0013] The three-layer ultrafiltrate perfusion device is composed of a polyethersulfone resin adsorption layer, a polystyrene resin adsorption layer and an activated carbon resin adsorption layer arranged in sequence from bottom to top;

[0014] The volumes of the polyethersulfone resin adsorption layer, the polystyrene resin adsorption layer and the activated carbon resin adsorption layer are 70-130 mL, 35-65 mL and 120-180 mL respectively;

[0015] The three-layer ultrafiltrate perfusion device can continuously absorb metabolic wastes and toxins such as urea, uric acid, creatinine and β2-microglobulin in the ultrafiltrate;

[0016] The polyethersulfone resin adsorption layer is filled with a plurality of polyethersulfone resin urea adsorption microspheres; the diameter of the polyethersulfone resin urea adsorption microspheres is 800-1500 μm.

[0017] As a preferred technical solution, an arterial pressure detector is arranged between the arterial clamp and the blood pump; a pre-filtration pressure detector is arranged between the arterial pot and the blood filter; a venous pressure detector is arranged between the bubble detector and the venous clamp; and an ultrafiltrate pressure detector is arranged between the blood filter and the ultrafiltrate pump.

[0018] As a preferred technical solution, the blood filter is provided with a blood inlet, a blood outlet and an ultrafiltrate outlet, wherein the blood inlet and the blood outlet are connected to the blood circulation part, and the ultrafiltrate outlet is connected to the ultrafiltrate purification part. The blood inlet and the blood outlet are connected to the blood circulation part, and the ultrafiltrate outlet is connected to the ultrafiltrate purification part. The blood passes through the blood filter to produce an ultrafiltrate containing metabolic waste and toxins. After being processed by the ultrafiltrate purification part, the purified ultrafiltrate returns to the blood circulation again.

[0019] As a preferred technical solution, the polystyrene resin adsorption layer is filled with a plurality of polystyrene resin adsorption microspheres; the diameter of the polystyrene resin adsorption microspheres is 500-1000 μm.

[0020] As a further preferred technical solution, the activated carbon resin adsorption layer is filled with a plurality of activated carbon resin adsorption microspheres; the diameter of the activated carbon resin adsorption microspheres is 800-1200 μm.

[0021] Appropriate adsorption layer volume and adsorption microsphere diameter can ensure the purification effect.

[0022] When in use, the patient's blood vessels are connected to the blood circulation pipeline in the artificial kidney device of the present application, and the patient's blood enters the blood circulation part from the arterial end of the pipeline and returns to the patient's blood vessels from the venous end of the pipeline.

[0023] This regimen uses heparin anticoagulation, and an appropriate amount of heparin is added through the heparin inlet at the beginning and during treatment to maintain the patency of the blood circulation circuit.

[0024] The blood pump controls the blood flow rate of the blood circulation part, and the blood flow rate is 100-150 mL / min; the ultrafiltrate pump controls the ultrafiltrate flow rate of the ultrafiltrate purification part, and the ultrafiltrate flow rate is 20-30 mL / min.

[0025] The arterial pot is close to the arterial end of the blood circulation pipeline, and the venous pot is close to the venous end of the blood circulation pipeline. Both are mainly used to clear bubbles in the blood circulation pipeline and prevent air from entering the blood circulation pipeline and causing thrombosis.

[0026] The arterial pressure detector, pre-filtration pressure detector, ultrafiltrate pressure detector and venous pressure detector respectively detect the blood pressure at the arterial end, the blood inlet pressure of the blood filter, the ultrafiltrate outlet pressure of the blood filter and the blood pressure at the venous end, and alarm when the preset pressure range is exceeded.

[0027] The bubble detector detects bubbles in the blood circulation line and sounds an alarm when the preset maximum bubble amount is exceeded.

[0028] The effective membrane area of ​​the hemofilter is 1.6-2.0 m 2 The ultrafiltration coefficient is 60-75 mL / h / mmHg, the blood chamber capacity is 90-110 mL, and the screening coefficients for urea, uric acid, creatinine and β2-microglobulin are not less than 0.95, 0.85, 0.9 and 0.3 respectively.

[0029] Compared with the existing wearable artificial kidney devices and technologies, the advantages of the utility model are:

[0030] 1. No liquid consumables are used, including dialysate and replacement fluid, and no complicated water treatment system and dialysate regeneration device are required, which increases the portability of the device and reduces the difficulty of operation.

[0031] 2. The blood filter is used to produce ultrafiltrate containing metabolic waste, toxins and water, and then the ultrafiltrate perfusion device is used to efficiently remove metabolic waste and toxins in the ultrafiltrate. The purified ultrafiltrate will return to the blood again, continuously reducing the content of metabolic waste and toxins in the blood. In addition, during the treatment process, the dehydration effect can be achieved by draining part of the ultrafiltrate.

[0032] 3. Polyethersulfone resin urea adsorption microspheres were proposed and used to achieve urea removal by direct adsorption, avoiding the safety risk of "urease decomposition-adsorption" strategy for urea removal. The urea adsorption microspheres can also be used in the design of other wearable artificial kidney devices, especially to solve the problem of urea removal in dialysate regeneration.

[0033] 4. The consumables used in this device are mainly pipelines, blood filters and three-layer dialysate perfusion devices, which do not need to be replaced during treatment. The three types of adsorption microspheres contained in the three-layer dialysate perfusion device are simple to prepare and low in cost, which significantly reduces the patient's treatment costs and is suitable for ordinary low-income families. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The utility model is a schematic diagram of the principle of a filtration perfusion type artificial kidney device.

[0035] In the figure: 1. arterial clamp; 2. arterial pressure detector; 3. blood pump; 4. heparin inlet; 5. arterial pot; 6. pre-filtration pressure detector; 7. blood filter; 8. ultrafiltrate pressure detector; 9. ultrafiltrate pump; 10. ultrafiltrate clamp; 11. ultrafiltrate collector; 12. three-layer ultrafiltrate perfusion device; 121. polyethersulfone resin adsorption layer; 122. polystyrene resin adsorption layer; 123. activated carbon resin adsorption layer; 13. venous pot; 14. bubble detector; 15. venous pressure detector; 16. venous clamp. DETAILED DESCRIPTION

[0036] The utility model will be further described below in conjunction with the accompanying drawings.

[0037] Embodiment 1-3:

[0038] like Figure 1As shown, a filtration perfusion type artificial kidney device comprises a blood circulation part and an ultrafiltrate purification part; wherein the blood circulation part comprises an arterial clamp 1, an arterial pressure detector 2, a blood pump 3, a heparin inlet 4, an arterial pot 5, a pre-filtration pressure detector 6, a blood filter 7, a venous pot 13, a bubble detector 14, a venous pressure detector 15 and a venous clamp 16 which are sequentially arranged along the blood flow direction; the ultrafiltrate purification part comprises an ultrafiltrate pressure detector 8, an ultrafiltrate pump 9 and a three-layer ultrafiltrate perfusion device 12 which are sequentially arranged along the ultrafiltrate flow direction; an ultrafiltrate clamp 10 and an ultrafiltrate collector 11 are arranged between the ultrafiltrate pump 9 and the three-layer ultrafiltrate perfusion device 12, and the direction of the arrow in the figure is the blood / ultrafiltrate flow direction;

[0039] The above structural units, as understood by those skilled in the art, can be obtained commercially unless otherwise specified;

[0040] The blood filter 7 is provided with a blood inlet, a blood outlet and an ultrafiltrate outlet, wherein the blood inlet and the blood outlet are connected to the blood circulation part, and the ultrafiltrate outlet is connected to the ultrafiltrate purification part;

[0041] The three-layer ultrafiltrate perfusion device 12 is composed of a polyethersulfone resin adsorption layer 121, a polystyrene resin adsorption layer 122 and an activated carbon resin adsorption layer 123 arranged in sequence from top to bottom; wherein the polyethersulfone resin adsorption layer 121 is filled with a plurality of polyethersulfone resin urea adsorption microspheres, and the diameter of the polyethersulfone resin urea adsorption microspheres is 800-1500 μm; the polystyrene resin adsorption layer 122 is filled with a plurality of polystyrene resin adsorption microspheres, and the diameter of the polystyrene resin adsorption microspheres is 500-1000 μm; the activated carbon resin adsorption layer 123 is filled with a plurality of activated carbon resin adsorption microspheres, and the diameter of the activated carbon resin adsorption microspheres is 800-1200 μm.

[0042] Before the treatment begins, connect the pipelines of the blood circulation part and the ultrafiltrate purification part; open the arterial clamp 1 and the venous clamp 16, open the blood pump 3, open the blood inlet and blood outlet of the blood filter 7, keep the ultrafiltrate outlet of the blood filter 7 closed, and introduce physiological saline and heparin saline from the arterial end of the blood circulation pipeline to flush the pipeline of the blood circulation part so that the pipeline is heparinized. At the same time, use the arterial pot 5 and the venous pot 13 to remove bubbles in the pipeline. After all bubbles in the pipeline are removed, turn off the blood pump 3, close the arterial clamp 1 and the venous clamp 16.

[0043] During the treatment, the pipeline connecting the patient's blood vessels and the blood circulation part is opened, the arterial clamp 1 and the venous clamp 16 are opened, the starting dose of heparin is added through the heparin inlet 4, and the blood is drawn and the blood flow rate is controlled by the blood pump 3. The blood flow rate gradually increases from 50 mL / min during blood drawing, and the final blood flow rate is controlled to 100-150 mL / min. The patient's blood enters the blood circulation part from the arterial end of the pipeline and returns to the patient's blood vessels from the venous end. In the blood circulation part, the blood passes through the arterial clamp 1, the arterial pressure detector 2, the blood pump 3, the heparin inlet 4, the arterial pot 5, the pre-filtration pressure detector 6, the blood filter 7, the venous pot 13, the bubble detector 14, the venous pressure detector 15, and the venous clamp 16 in sequence before returning to the patient's blood vessels. The ultrafiltrate outlet of the blood filter 7 is opened, the ultrafiltrate pump 9 is turned on, the ultrafiltrate flow rate is controlled to 20-30 mL / min, and the ultrafiltrate clamp 10 is kept closed. The blood passes through the blood filter 7 to generate ultrafiltrate, and the ultrafiltrate enters the ultrafiltrate purification part, and then returns to the blood circulation pipeline after passing through the ultrafiltrate pressure detector 8, the ultrafiltrate pump 9, and the three-layer ultrafiltrate perfusion device 12. During the treatment process, according to the demand for dehydration, the ultrafiltrate clamp 10 is opened to discharge part of the ultrafiltrate into the ultrafiltrate collector 11.

[0044] After the treatment is finished, the ultrafiltrate outlet of the blood filter 7 is closed first, and after the ultrafiltrate of the ultrafiltrate purification part is completely transferred back to the blood circulation, the ultrafiltrate pump 9 is closed, and the connection between the ultrafiltrate purification part and the blood circulation part is disconnected. The arterial clamp 1 and the blood pump 3 are closed, and after the arterial end of the pipeline is disconnected from the patient's blood vessel, the arterial end of the pipeline is connected to physiological saline, and then the arterial clamp 1 and the blood pump 3 are opened again. After the physiological saline passes through the pipeline of the blood circulation part, it returns to the patient's blood vessel together with the remaining blood in the pipeline. After all the blood in the pipeline is transferred back to the patient's blood vessel, the venous clamp 16 and the blood pump 3 are closed.

[0045] The effective membrane area of ​​the hemofilter is 1.6-2.0 m 2 The ultrafiltration coefficient is 60-75 mL / h / mmHg, the blood chamber capacity is 90-110 mL, and the screening coefficients for urea, uric acid, creatinine and β2-microglobulin are not less than 0.95, 0.85, 0.9 and 0.3 respectively.

[0046] In Examples 1-3, the volumes of the polyethersulfone resin adsorption layer, the polystyrene resin adsorption layer and the activated carbon resin adsorption layer in the three-layer ultrafiltrate perfusion device are shown in Table 1. Examples 1-3 were applied to a blood purification pilot experiment, and the initial concentrations of urea, uric acid, creatinine and β2-microglobulin in the blood were 10 mmol / L, 400 μmol / L, 200 μmol / L and 10 mg / L, respectively. The treatment was carried out for 4 hours, and the clearance rates of urea, uric acid, creatinine and β2-microglobulin were shown in Table 2.

[0047] Table 1 Volumes of the polyethersulfone resin adsorption layer, polystyrene resin adsorption layer and activated carbon resin adsorption layer in the three-layer ultrafiltrate perfusion device of each embodiment

[0048] Polyethersulfone resin adsorption layer (mL) Polystyrene resin adsorption layer (mL) Activated carbon resin adsorption layer (mL) Example 1 70 50 180 Example 2 100 60 140 Example 3 130 40 130

[0049] Table 2 Clearance rates of urea, uric acid, creatinine and β2-microglobulin in various examples

[0050] Urea (%) Uric acid (%) Creatinine (%) β2-microglobulin (%) Example 1 35.1 82.9 86.1 21.9 Example 2 48.4 75.4 77.3 29.6 Example 3 55.5 63.3 58.7 16.0

[0051] The present invention is not limited to the above optional implementation modes. The above specific implementation modes are only preferred implementation examples of the present invention and should not be understood as limiting the protection scope of the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A wearable filtration perfusion artificial kidney device, characterized in that: It includes a blood circulation part and an ultrafiltrate purification part; wherein, The blood circulation part comprises an arterial clamp (1), a blood pump (3), a heparin inlet (4), an arterial pot (5), a blood filter (7), a venous pot (13), a bubble detector (14) and a venous clamp (16) which are arranged in sequence along the blood flow direction; The ultrafiltrate purification part comprises an ultrafiltrate pump (9) and a three-layer ultrafiltrate perfusion device (12) arranged in sequence along the flow direction of the ultrafiltrate; an ultrafiltrate clamp (10) and an ultrafiltrate collector (11) are arranged between the ultrafiltrate pump (9) and the three-layer ultrafiltrate perfusion device (12); The three-layer ultrafiltrate perfusion device (12) is composed of a polyethersulfone resin adsorption layer (121), a polystyrene resin adsorption layer (122) and an activated carbon resin adsorption layer (123) which are arranged in sequence from bottom to top; The volumes of the polyethersulfone resin adsorption layer (121), the polystyrene resin adsorption layer (122), and the activated carbon resin adsorption layer (123) are 70-130 mL, 35-65 mL, and 120-180 mL, respectively; The polyethersulfone resin adsorption layer (121) is filled with a plurality of polyethersulfone resin urea adsorption microspheres; the diameter of the polyethersulfone resin urea adsorption microspheres is 800-1500 μm.

2. The wearable filtration perfusion artificial kidney device according to claim 1, characterized in that: An arterial pressure detector (2) is provided between the arterial clamp (1) and the blood pump (3); a pre-filtration pressure detector (6) is provided between the arterial pot (5) and the blood filter (7); a venous pressure detector (15) is provided between the bubble detector (14) and the venous clamp (16); and an ultrafiltrate pressure detector (8) is provided between the blood filter (7) and the ultrafiltrate pump (9).

3. The wearable filtration perfusion artificial kidney device according to claim 1, characterized in that: The blood filter (7) is provided with a blood inlet, a blood outlet and an ultrafiltrate outlet, wherein the blood inlet and the blood outlet are connected to the blood circulation part, and the ultrafiltrate outlet is connected to the ultrafiltrate purification part.

4. The wearable filtration perfusion artificial kidney device according to claim 1, characterized in that: The polystyrene resin adsorption layer (122) is filled with a plurality of polystyrene resin adsorption microspheres; the diameter of the polystyrene resin adsorption microspheres is 500-1000 μm.

5. The wearable filtration perfusion artificial kidney device according to claim 1, characterized in that: The activated carbon resin adsorption layer (123) is filled with a plurality of activated carbon resin adsorption microspheres; the diameter of the activated carbon resin adsorption microspheres is 800-1200 μm.

Citation Information

Cited By

  • Pre-charging and exhausting system and pre-charging and exhausting method for blood purification

    CN122070944A